| 发明名称 |
Dual GLP-1/Glucagon Receptor Agonists |
| 摘要 |
The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake |
| 申请公布号 |
US2015164997(A1) |
申请公布日期 |
2015.06.18 |
| 申请号 |
US201414569387 |
申请日期 |
2014.12.12 |
| 申请人 |
Sanofi |
发明人 |
Haack Torsten;Wagner Michael;Henkel Bernd;Stengelin Siegfried;Evers Andreas;Bossart Martin;Kadereit Dieter |
| 分类号 |
A61K38/26;A61K45/06;C07K14/605 |
主分类号 |
A61K38/26 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A peptidic compound having the formula (I):
R1—Z—R2 (I)wherein Z is a peptide moiety having the formula (II)(II)His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Leu-Leu-Asp-Glu-Gln-X18-Ala-Lys-Asp-Phe-Ile-Glu-Trp-Leu-Ile-Ala-Gly-Gly-Pro-X32-Ser-Gly-Ala-Pro-Pro-Pro-Ser X2 represents an amino acid residue selected from Ser, D-Ser or Aib, X3 represents an amino acid residue selected from Gln or His, X18 represents an amino acid residue selected from Arg or Leu, X32 represents an amino acid residue selected from Ser or Val, R1 represents NH2, and R2 represents OH or NH2, or a salt or solvate thereof. |
| 地址 |
Paris FR |
